NurExone Biologic (TSXV:NRX), a pharmaceutical company developing a treatment for the reversal or reduction of paralysis following Spinal Cord Injury, is one of the latest new listings on the TSX Venture Exchange. This is a unique, advanced treatment for reversing paralysis and improving the quality of life of patients following spinal cord injury using bio-guided exosomes loaded with modified siRNA sequence.
Additional Information:
Video Transcript:
NurExone Biologic (TSXV:NRX), a pharmaceutical company, is one of the latest new listings on the TSX Venture Exchange, trading under the symbol “NRX”, following its RTO with Enerspar Corp.
NurExone is developing a treatment for the reversal or reduction of paralysis following Spinal Cord Injury.
This is a unique, advanced treatment for reversing paralysis and improving the quality of life of patients following spinal cord injury using bio-guided exosomes loaded with modified siRNA sequence.
Exosomes, which are endosome-derived small membrane vesicles, approximately 30 to 150 nano metres in diameter, have emerged as promising nanocarriers for drug delivery and targeted therapy, as alternatives to stem cell therapy.
This technology, which has been successfully used in animal studies, after it is approved in clinical trials, can be used to treat various conditions such as spinal cord injury, traumatic brain injury, and other brain and neurological indications.
NurExone holds an exclusive worldwide license to develop and commercialize the technology by the Technion - Israel Institute of Technology, Haifa and Tel Aviv University, both located in Israel.
The company also recently obtained an additional exclusive global license to an exosome manufacturing process developed at the Technion - Israel Institute of Technology, Haifa.
NurExone will be responsible for ongoing exosome research, management of clinical studies and commercialization of the technology for different indications not limited to the central nervous system.
According to the World Health Organization, the estimated global spinal cord injury incidence is 40 to 80 new cases per million population per year, based on quality country-level incidence studies of spinal cord injury from all causes.
This means that every year, between 250,000 and 500,000 people become spinal cord injured worldwide.
According to the Rick Hansen Institute, the estimated economic cost of traumatic spinal cord injury for newly injured Canadians is $2.7 billion annually.
There are approximately 4,300 new cases each year, which is estimated to reach 5,800 by 2030.
Vehicle crashes are the most recent leading cause of injury, closely followed by falls.
Acts of violence, primarily gunshot wounds, and sports/recreation activities are also relatively common causes.
The shares are trading at $0.80.
For more information, please visit the company’s website www.NurExone.com, contact Dr. Lior Shaltiel, CEO, at 972-52-4803034 or email info@NurExone.com.
